Exelixis
Focus: Exelixis is an oncology-focused biotechnology company headquartered in Alameda, CA, specializing in small-molecule tyrosine kinase inhibitors. The company operates as a mid-cap biotech with a highly concentrated revenue base from its flagship product.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Open Jobs
54+7 this month
Growing — net +7 jobs in 30d
70 jobs added vs 63 removed. Steady team buildout.
Should You Work at Exelixis?
AI assessmentExelixis offers strong growth potential for those seeking early-career exposure to oncology development and clinical operations, but carries significant execution risk tied to unproven pipeline assets replacing a single aging revenue engine.
Why Work Here
- Single blockbuster asset (CABOMETYX) generating $1.1B in Part D spending across three major cancer indications (RCC, prostate, HCC)
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$1.1B Part DStable
Peak
Help build intelligence for Exelixis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.